Megan T. Sniecinski
2021
Compensation breakdown
| Option Awards | $6,952,056 |
|---|---|
| Salary | $286,192 |
| Other | $690,876 |
| Total | $7,929,124 |
Sniecinski received $7M in option awards, accounting for 88% of the total pay in 2021.
Sniecinski also received $286.2K in salary and $690.9K in other compensation.
Rankings
In 2021, Megan T. Sniecinski's compensation ranked 1,460th out of 12,415 executives tracked by ExecPay. In other words, Sniecinski earned more than 88.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,460 out of 12,415 | 88th |
Division Manufacturing | 528 out of 5,505 | 90th |
Major group Chemicals And Allied Products | 198 out of 2,375 | 92nd |
Industry group Drugs | 164 out of 2,096 | 92nd |
Industry Biological Products, Except Diagnostic Substances | 44 out of 449 | 90th |
Pay ratio
| Megan T. Sniecinski's Pay | $7,929,124 |
|---|---|
| Median Employee's Pay | $273,522 |
| Pay Ratio | 29to 1 |
In 2021, the annual total compensation of Megan T. Sniecinski was $7,929,124.
The annual total compensation of the median employee at BioCryst Pharmaceuticals was $273,522.
The ratio of Megan T. Sniecinski's pay to the pay of median employee was therefore 29 to one.
Sniecinski's colleagues
We found five more compensation records of executives who worked with Megan T. Sniecinski at BioCryst Pharmaceuticals in 2021.
2021
Jon Stonehouse
BioCryst Pharmaceuticals
Chief Executive Officer
2021
Helen Thackray
BioCryst Pharmaceuticals
Chief R&D Officer
2021
Anthony Doyle
BioCryst Pharmaceuticals
Chief Financial Officer
2021
William Sheridan
BioCryst Pharmaceuticals
Chief Medical Officer
2021
Yarlagadda Babu
BioCryst Pharmaceuticals